ANDA 202624, held by Am Regent. Ganciclovir Sodium.
As of Nov 16, 2026, ANDA 202624 (Ganciclovir Sodium), held by Am Regent, was first approved by FDA on Sep 18, 2013, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 18, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ganciclovir SodiumEQ 500MG BASE/VIAL · injectable;injection | Ganciclovir Sodium | Discontinued |
| Jun 8, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 8, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 18, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters